logo-loader

Full interview: Scancell back in the clinic with a phase II trial of its flagship skin cancer treatment

Published: 13:32 19 Aug 2019 BST

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment.

The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Keytruda.

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 19/9/23